

- **Name:** Heejung Chae
 - **Current Position & Affiliation:** Clinical assistant professor, Seoul National University Bundang Hospital
 - **Country:** Korea
-

• **Educational Background:**

2013 University of Ulsan College of Medicine, M.D.

2018 University of Ulsan College of Medicine, M.S.

2020 University of Ulsan College of Medicine, Ph.D.

• **Professional Experience:**

2013 – 2014 Internship, Asan Medical Center

2014 – 2018 Resident, Internal Medicine Asan Medical Center

2018 – 2019 Fellowship, Medical Oncology Asan Medical Center

2019 - 2025 Clinical Assistant Professor, Medical Oncology National Cancer Center Korea

2025 - Present Clinical Assistant Professor, Medical Oncology Seoul National University Bundang Hospital

• **Professional Organizations:**

2025 – Present Education committee Vice Chair, Korean Breast Cancer Society

2023 – Present Scientific Committee, Korean Breast Cancer Society

2023 – Present Asian Breast Cancer Networking Committee, Korean Breast Cancer Society

2021 – Present Breast Cancer Committee, Korean Cancer Study Group

2021 – Present Member, Korean Society of Medical Oncology

2021 – Present Member, American Association for Cancer Research

2020 – Present Member, Korean Breast Cancer Society

2019 – Present Member, American Society of Clinical Oncology

2018 – Present Member, Korean Cancer Association

2016 – Present Member, European Society for Medical Oncology

• **Main Scientific Publications:**

1. Chae H, Kim D, Yoo C, Kim K-P, Jeong JH, Chang H-M, Lee SS, Park DH, Song TJ, Hwang S, Kim K-H, Song G-W, Ahn C-S, Lee JH, Hwang DW, Kim SC, Jang SJ, Hong SM, Kim TW, Ryoo B-Y. Therapeutic Relevance of Targeted Sequencing in Management of Patients with Advanced Biliary Tract Cancer: DNA Damage Repair Gene Mutations as a Predictive Biomarker. *Eur J Cancer*. 2019 Oct;120:31-39.
2. Chae H, Jeong H, Cheon J, Chon HJ, Ryu H, Kim I-H, Kang MJ, Jeong JH,

Ryoo B-Y, Kim K-P, Yoo C. Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis. *Ther Adv Med Oncol*. 2020; 12: 1758835920923424. Published online 2020 May 27.

3. Chae H, Cho H, Sa H-S, Kim KW, Chae EJ, Ryu J-S, Park CS, Huh J, Jang S, Yoon DH, Suh C. The limited role of comprehensive staging work-up in ocular adnexal extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue type (MALToma) with excellent prognosis. *Br J Haematol*. 2021 May;193(4):848-851
4. Chae H, Kim JE, Kim W, Lee J-S, Song SY, Lee MH, Chung HW, Cho K-J, Song JS, Ahn J-H. Clinicopathologic Characteristics and Clinical Outcome of Localized Liposarcoma: A Single Center Experience Over 25 Years and Evaluation of PD-L1 Expression. *Cancer Res. Treat*. 2022 Apr;54(2):579-589.
5. Chae H, Sim SH, Kwon Y, Lee EG, Han JH, Jung S-Y, Lee S, Kang H-S, Kim Y-J, Kim TH, Lee KS. Neoadjuvant chemotherapy with Concurrent Letrozole for Estrogen Receptor-Positive and HER2-Negative Breast Cancer: An Open-Label, Single-Center, Nonrandomized Phase II Study (NeoCHAI). *Cancers (Basel)*. 2024 Sep 10;16(18):3122.